IDAHO FALLS, Idaho, Nov. 21, 2016 /PRNewswire/ -- International Isotopes Inc. (OTCQB: INIS) (the "Company") announces that it has submitted an abbreviated new drug application (aNDA) to the U.S. Food and Drug Administration (FDA) for its I 3odine/MAX ™ sodium iodide radiopharmaceutical product. This is the first application submitted to the FDA by any company for a generic sodium iodide product, and that status should justify an expedited FDA review. Steve T. Laflin, President and CEO of the Company, said, "Our submittal of this application is a significant milestone for the Company. For many decades sodium iodide has proven itself to be an essential product for the treatment and diagnosis of diseases of the thyroid, thyroid cancer, and hyperthyroidism and for use in investigational and clinical trials for the treatment of breast, lung, prostate, and ovarian cancers. We believe that, if approved, our I 3odine/MAX ™ product will offer distinct advantages to patients, pharmacies, and hospitals while being very competitively priced. Current sales of our radiochemical sodium iodide product are already a significant percentage of the Company's total revenue, and we expect that after FDA approval, sales of the I 3odine/MAX ™ drug product could have a significant positive impact on Company revenue." "With this product submittal to the FDA, we intend to now shift our focus to address preparing submittals for other radiopharmaceutical products we have identified for our new product pipeline."